Open Access

Knockdown of METTL14 suppresses the malignant progression of non‑small cell lung cancer by reducing Twist expression

  • Authors:
    • Fang Yang
    • Wei-Qi Yuan
    • Juan Li
    • Yi-Qin Luo
  • View Affiliations

  • Published online on: October 21, 2021     https://doi.org/10.3892/ol.2021.13108
  • Article Number: 847
  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Non‑small cell lung cancer (NSCLC) is one of the most malignant cancer types. N6‑methyladenosine (m6A), an abundant eukaryotic mRNA modification, has been observed in multiple diseases, particularly cancer. Methyltransferase‑like 14 (METTL14) is a central component of the m6A methyltransferase complex and has been reported to promote tumor development in several cancer types. The present study aimed to investigate the role of METTL14 in NSCLC. Relevant clinical and mRNA sequencing data for m6A‑related genes were downloaded from The Cancer Genome Atlas database. R software was used to evaluate the expression of m6A regulators in NSCLC. The biological functions of METTL14 were evaluated using Cell Counting Kit‑8, colony formation, Transwell migration and western blot analyses. The results demonstrated that METTL14 expression was upregulated in NSCLC tissues and cell lines, and its expression was high in cancer tissues from patients with NSCLC with all four stages (I, II, III and IV) of disease. METTL14 downregulation inhibited cell proliferation and migration in A549 and SK‑MES‑1 lung cancer cell lines. Knockdown of METTL14 in lung cancer cell lines increased E‑cadherin expression and suppressed N‑cadherin expression. Furthermore, METTL14 downregulation reduced the expression levels of the transcription factor Twist and the p‑AKT/AKT ratio. In conclusion, the present findings revealed that silencing of METTL14 suppressed NSCLC malignancy by inhibiting Twist‑mediated activation of AKT signaling. These data suggest that METTL14 may be a potential therapeutic target for NSCLC.
Something has gone wrong

HTTP Error 400

Well this is embarrassing. Something has gone wrong. Hopefully it is a transient error that will go away if you retry.

If the problem persists if you email our System Administrators letting them know what you were doing and telling them it was because:

Exception evaluating SpringEL expression: "dispArt?.images" (template: "article" - line 384, col 9)

and then they can get to work fixing it